Aggressive B-Cell Lymphoma
The latest news, research, and perspectives in aggressive B-cell lymphoma. These fast-growing non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma, arise at different stages of B-cell development.
Advertisement
Advertisement
Dr. Bertoni and colleagues characterized two small nucleolar RNAs that exert tumor suppressor activity in DLBCL cells.
Adding ofatumumab to reduced intensity conditioning is safe and effective in high-risk B-cell non-Hodgkin lymphoma.
The approval was declined due to the enrollment status of the confirmatory trials.
This manufacturing process change results in a shorter manufacturing time for axi-cel from 16 days to 14 days.
ZUMA-7 showed that axi-cel significantly improved OS compared with standard of care in relapsed or refractory LBCL.
Dr. Eyre and the hosts discuss lymphoma abstracts from ASH 2023, including the FLAIR trial and the SYMPATICO trial.
The study included 16 baseline and 18 post-infusion tumor samples from 26 patients.
In this episode of The HemOnc Pulse, Alan Skarbnik, MD, of Novant Health, discusses practice-changing research in DLBCL.
The results were presented at the 65th American Society of Hematology Annual Meeting & Exposition in San Diego.
Researchers collected serial peripheral blood mononuclear cell samples from patients with R/R LBCL treated with axi-cel.
The phase II, multicenter, single-arm study is assessing axi-cel for frontline treatment in patients with high-risk LBCL.
The analysis assessed the impacts of bridging therapy when used in patients receiving axi-cel for large B-cell lymphoma.
Dr. Spiegel shared five-year data from a retrospective study of 298 patients with LBCL who received axi-cel.
Polatuzumab-based bridging was associated with high overall response rate and complete response rate.
The SEER database was used to examine disparities in incidence and survival outcomes between different races.
Liso-cel "should continue to be a really good option for these older patients," Dr. Sehgal said.
Julie Vose, MD, MBA, discussed the use of epcoritamab in patients with diffuse large B-cell lymphoma (DLBCL).
Adults older than 65 and newly diagnosed with DLBCL or DLBCL/high-grade BCL with MYC and BCL2 rearrangements were surveyed.
Researchers examined registry data for patients with previously untreated DLBCL or high-grade BCL treated with R-CHOP.
One-time liso-cel infusion demonstrated durable responses in R/R LBCL.
After a median of four years of follow-up, participants in the pivotal ZUMA-2 study had a median OS of nof nearly five years.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
